Does Medicare Cover Aduhelm or Its Alternatives?

Medicare does not cover Aduhelm anymore because the drug itself is gone: Biogen discontinued aducanumab in early 2024, and it is no longer sold in the United States.1Biogen. Biogen to Realign Resources for Alzheimer’s Disease Franchise The coverage rules that once governed Aduhelm, however, still shape what Medicare will pay for today. Those rules now apply to the two anti-amyloid Alzheimer’s drugs that remain on the market, Leqembi and Kisunla, and Medicare Part B will cover either one when a patient has early-stage Alzheimer’s, confirmed amyloid in the brain, and a prescribing clinician enrolled in a qualifying patient registry.

Why Aduhelm Is No Longer the Question

Biogen pulled Aduhelm from the market in 2024 to shift resources to other Alzheimer’s work. Uptake had been low from the start: because Aduhelm never advanced past the FDA’s accelerated approval pathway, Medicare paid for it only inside randomized controlled trials, and few patients ever received it that way even after Biogen cut the annual price to $28,200.2Biogen. Biogen Announces Reduced Price for ADUHELM to Improve Access for Patients with Early Alzheimer’s Disease If you came to this question because a family member was told about Aduhelm, the practical answer is that the relevant choice today is between Leqembi and Kisunla.

What Medicare Covers in Place of Aduhelm

CMS issued a National Coverage Determination in April 2022 covering all FDA-approved monoclonal antibodies that target amyloid for Alzheimer’s disease.3Centers for Medicare & Medicaid Services. CMS Finalizes Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease That determination is still in force and governs Leqembi and Kisunla. Both drugs have traditional FDA approval, which puts them on the broader of two coverage tracks: Medicare pays for treatment as long as the prescribing clinician reports patient data through a CMS-approved registry. Treatment given outside an approved study setting is not covered.4Centers for Medicare & Medicaid Services. Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (AD)

Leqembi (Lecanemab)

Leqembi received traditional FDA approval in July 2023, which moved it onto the registry-based coverage track and made it far more accessible than Aduhelm ever was.5U.S. Food and Drug Administration. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval The standard course is an intravenous infusion every two weeks at a wholesale price of $26,500 per year for a patient of average weight.6Eisai. Eisai’s Approach to U.S. Pricing for LEQEMBI A self-injected version called LEQEMBI IQLIK was approved for maintenance dosing and launched in October 2025.7Eisai. FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Self-administered drugs typically fall under Part D rather than Part B, so cost-sharing for the injectable form may not match the IV figures below. Leqembi treatment is ongoing and does not have a defined endpoint.

Kisunla (Donanemab)

Kisunla was approved by the FDA on July 2, 2024. Its distinguishing feature is that patients can stop treatment once a follow-up PET scan shows amyloid plaques reduced to minimal levels. Trial data support assessing response at 12 months, and many patients may finish treatment around that point.8Eli Lilly. What Is the Optimum Duration of Treatment with Kisunla The list price is $717.79 per vial; total cost depends on dosing and how long therapy runs.9Eli Lilly. Kisunla (donanemab-azbt) Injection for Intravenous Use – Pricing Information For families thinking about lifetime cost, the possibility of a finite course matters.

Who Qualifies for Coverage

The clinical criteria are the same for both drugs. You need a clinical diagnosis of mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia, plus confirmed amyloid beta pathology.10Centers for Medicare & Medicaid Services. Medicare Coverage Policy for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease Amyloid is confirmed by either an amyloid PET scan or cerebrospinal fluid biomarker testing. People with moderate or advanced Alzheimer’s do not qualify.

The second requirement is often the one that trips patients up. The prescribing clinician has to be enrolled in a CMS-approved registry, such as the Alzheimer’s National Registry for Treatment and Diagnostics or one of several registries run by academic medical centers.11Centers for Medicare & Medicaid Services. Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease (AD) – Coverage with Evidence Development Clinic staff submit patient data through a CMS portal at the start of treatment and every six months for up to 24 months. Not every neurologist or memory clinic has signed up, and patients in rural areas sometimes have to travel to a participating site. Confirm your prospective treatment center is enrolled before you start the diagnostic workup.

What You Pay Under Part B in 2026

IV-infused anti-amyloid drugs fall under Medicare Part B because they are given by a clinician in an outpatient setting rather than taken at home.12Medicare.gov. Prescription Drugs (Outpatient) Part B pays for both the drug and the infusion service.

You pay the Part B deductible first, which is $283 for 2026, and then 20% coinsurance on the Medicare-approved amount for everything after that. For Leqembi at the $26,500 list price, that works out to roughly $5,500 a year in coinsurance for the drug alone, plus coinsurance on the infusion fees. Actual figures vary because Medicare’s approved amount can differ from the list price. For Kisunla, out-of-pocket spending turns on how many months of infusions you need before a scan confirms amyloid clearance. The standard Part B premium is $202.90 a month in 2026, which you pay whether or not you receive these drugs.13Centers for Medicare & Medicaid Services. 2026 Medicare Parts A and B Premiums and Deductibles

How Medigap and Medicare Advantage Change the Math

A Medigap policy can take a large bite out of these numbers. Most plans cover the 20% Part B coinsurance, which on a $26,500 drug is thousands of dollars a year. Check your plan letter, because some cover the full coinsurance and others cover only part of it.

Medicare Advantage plans have to follow the same National Coverage Determination. They cannot refuse to cover Leqembi or Kisunla for a patient who meets the registry and clinical criteria. What they can do is restructure your cost-sharing: copays or tiers instead of flat coinsurance, and an annual out-of-pocket maximum that caps your total spending. With a drug this expensive, that cap can leave you better off than Original Medicare without a Medigap policy. Call your plan to find out how it handles Part B drugs under the Alzheimer’s NCD before you commit to a treatment plan.

Diagnostic Tests and Safety Monitoring

Before treatment starts, you need the amyloid confirmation already mentioned, usually through an amyloid PET scan or cerebrospinal fluid testing. CMS removed its previous one-scan limit on amyloid PET in late 2023, and in most regions the scan is now covered as routine clinical care, with Medicare Administrative Contractors making local decisions. Medicare Advantage plans may process the claim differently.

APOE ε4 genetic testing sits in a different place. Leqembi’s FDA labeling recommends the test, because carriers of the ε4 variant face a higher risk of a side effect called amyloid-related imaging abnormalities, or ARIA. Most Medicare Administrative Contractors do not cover this test, so patients often pay out of pocket or go without.

ARIA, which can involve brain swelling or small bleeds, is the most serious safety concern with every drug in this class and is usually caught on MRI before symptoms appear. The FDA labeling requires a baseline brain MRI before treatment and periodic follow-up scans at set points: for Leqembi, before the 5th, 7th, and 14th infusions, with an immediate MRI if symptoms suggest ARIA between scheduled scans. These MRIs are covered under Part B as part of the treatment protocol, subject to the usual 20% coinsurance that Medigap generally picks up. Mild ARIA without symptoms may allow treatment to continue under closer watch; severe or recurrent ARIA usually means stopping the drug.